Teva PharmaceuticalsTEVA
About: Teva Pharmaceutical Industries, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: the central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.
Employees: 37,851
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
185% more call options, than puts
Call options by funds: $498M | Put options by funds: $175M
12% more funds holding in top 10
Funds holding in top 10: 25 [Q2] → 28 (+3) [Q3]
11% more capital invested
Capital invested by funds: $10.1B [Q2] → $11.2B (+$1.12B) [Q3]
1% more funds holding
Funds holding: 525 [Q2] → 531 (+6) [Q3]
1.04% more ownership
Funds ownership: 55.07% [Q2] → 56.1% (+1.04%) [Q3]
10% more repeat investments, than reductions
Existing positions increased: 189 | Existing positions reduced: 172
9% more first-time investments, than exits
New positions opened: 74 | Existing positions closed: 68
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
Barclays Balaji Prasad 48% 1-year accuracy 21 / 44 met price target | 27%upside $28 | Overweight Maintained | 18 Dec 2024 |
JP Morgan Chris Schott 24% 1-year accuracy 4 / 17 met price target | 19%downside $18 | Neutral Maintained | 21 Oct 2024 |
Financial journalist opinion
Based on 22 articles about TEVA published over the past 30 days
